Investigator

Elena Maccaroni

Dirigente Medico · Azienda Ospedaliero Universitaria delle Marche, Clinica Oncologica

EMElena Maccaroni
Papers(1)
Oncological Genetic C…
Institutions(1)
Azienda Ospedaliero U…

Papers

Oncological Genetic Counseling in Hereditary Breast and Ovarian Cancers and Lynch Syndrome High‐Risk Subjects: Evaluation of Efficacy and Outcomes Using the Genomics Outcome Scale

Background Validated tools assessing oncological genetic counseling (OGC) quality are lacking. Methods We assessed OCG effectiveness using italian‐translated version of the Genomics Outcome Scale (GOS) questionnaire. Clinical variables were collected and their association with different answers was assessed by Fisher′s exact test or Chi‐square test for either dichotomous or other categorical variables, respectively, with level of statistical significance p = 0.05. Results Between November 2024 and February 2025, 209 subjects who received the complete OGC program at Our Center responded to the questionnaire; median age was 56 years (25–81). Most (76%) had breast cancer, 72% received a negative test, 15% positive test, and 13% noninformative test with variant of unknown significance (VUS). Most patients answered affirmatively to Question 1, focused on OGC understanding: age ( p = 0.0181) and education ( p = 0.0028) yielded different answers. Question 2, assessing relatives risk understanding, was answered completely/partially affirmative by 94% of subjects: test result (negative noninformative vs. positive vs. VUS) was associated ( p = 0.0175) with different answers. To Question 3, related to concern, 65% confirmed their worry: education ( p = 0.0392) and cancer type ( p = 0.0128) yielded different answers. In Question 4, focused on surveillance understanding, 77% declared full or partial awareness, regardless of examined factors. In Question 5, enquiring decisional ability for themselves or family members, 72% stated they were completely/partially able to make decisions. Education ( p = 0.0287) and genetic test result ( p = 0.0090) yielded different answers. In Question 6, reflecting future planning, 69% responded completely/almost completely affirmatively, 17% were uncertain, and 14% responded partially/completely negatively, regardless of examined clinical factors. Conclusions: GOS questionnaire confirms that OGC is useful and effective to inform patients about their condition, surveillance, and prevention. Higher levels of empowerment were seen in younger patients and those with higher education.

43Works
1Papers
Colorectal Neoplasms, Hereditary NonpolyposisBreast NeoplasmsHereditary Breast and Ovarian Cancer SyndromeOvarian Neoplasms

Positions

2016–

Dirigente Medico

Azienda Ospedaliero Universitaria delle Marche · Clinica Oncologica

2014–

1-year term contract as Medical Oncologist at Centro Regionale di Genetica Oncologica-Dept of Medical Oncology, Università Politecnica delle Marche – AOU Ospedali Riuniti – Ancona, aimed at the development of the project “Identification of subjects who, due to genetic predisposition, have high risk of developing cancer, with the aim of enhancing prevention and screening programs”

Azienda Ospedaliero Universitaria delle Marche · Clinica di Oncologia Medica-Centro Regionale di Genetica Oncologica

2009–

Medical Oncology Postgraduate School Fellowship

Università Politecnica delle Marche Facoltà di Medicina e Chirurgia

2007–

Volunteer Fellow, Dept of Medical Oncology

Università Politecnica delle Marche Facoltà di Medicina e Chirurgia

Education

2025

Master di II livello in Genetica Oncologica

Università degli Studi di Pavia

2018

PhD Course in Human Health

Università Politecnica delle Marche Facoltà di Medicina e Chirurgia · Scienze Cliniche e Molecolari

2014

Board certificate in Medical Oncology (score 50/50 magna cum laude)

Università Politecnica delle Marche Facoltà di Medicina e Chirurgia

2008

Degree in Medicine (score 110/110 magna cum laude)

Università Politecnica delle Marche Facoltà di Medicina e Chirurgia

Country

IT